Arrowhead Research (ARWR) HBV Biology Dogma Changes; NVIDIA (NVDA) In Focus


Shares of Arrowhead Research Corp. (Nasdaq:ARWR) surged more than 6% in pre-market trading Monday as the company said that its investigational drug (ARC-52) for chronic hepatitis B infection showed robust and sustained anti-viral effects in a study of chimpanzees with the disease.

ARWR stock closed at $5.68, up $0.18 (or +3.27%) on the last trading session, and 903,407 of its shares exchanged hands during the day

Arrowhead Research, a biopharmaceutical company, has 59.50M Shares Outstanding, Market Capitalization (intraday) of $337.97M and ARWR stock 52-week range is between $4.35 and $9.36 per share



Brokerage firm Canaccord Genuity upgraded NVIDIA Corp. (Nasdaq:NVDA)‘s stock from a Hold to a Buy rating and raised its price target from $30.00 to $35.00

NVIDIA recently reported third quarter fiscal 2016 revenue of $1.305 billion, a 7% increase year over year, and non-GAAP net income of $255 million, or $0.46 per diluted share, compared to non-GAAP net income of $220 million, or $0.39 per diluted share in the same period the prior year

NVDA stock finished Friday’s market activity at $29.80, down $0.60 (or -1.97%), with a total volume of 7,323,501 shares traded

NVIDIA, which operates as a visual computing company, has 539.00M Shares Outstanding, Market Capitalization (intraday) of $16.06B and NVDA stock one-year range is $18.94 – $31.94 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at